Clinical trial · Observational
Tumor Regression Grade As Predictor of Adjuvant Therapy
Tumor Regression Grade As Predictor of Adjuvant Therapy Benefits in Patients with Esophageal Squamous Cell Carcinoma After Neoadjuvant Therapy
NCT06710665CI-TRIAL-00083154recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Neoadjuvant therapy followed by surgery is preferred for locally advanced esophageal squamous cell carcinoma, but the necessity of adjuvant therapy remains controversial. Tumor regression grade reflects the response to neoadjuvant therapy and may predict patient prognosis, yet its role in guiding adjuvant therapy remains unexplored.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Esophageal Squamous Cell Carcinoma (ESCC) | Esophageal Squamous Cell Carcinoma | ONTOLOGY_EXACT | 0.85 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Chemotherapy | Drug | Chemotherapy | ALIAS |
Design
Arms and outcomes
Arms (2)
- label
- Good responders
- description
- Good responders (TRG 0-1). The pathologic report of the patient after neoadjuvant combined surgery
- interventionNames
- Drug: Chemotherapy
- label
- Poor responders
- description
- Poor responders (TRG 2-3). The pathologic report of the patient after neoadjuvant combined surgery
- interventionNames
- Drug: Chemotherapy
Primary outcomes (1)
- measure
- Overall survival
- timeFrame
- for patients surviving at least 90 days after surgery
- description
- time from diagnosis until death
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: (I) underwent R0 resection with either two-field or three-field lymphadenectomy (II) received neoadjuvant therapy such as preoperative radiotherapy, chemoradiotherapy, or combined immunotherapy (III) had esophageal squamous cell carcinoma pathology. Exclusion Criteria: (I) Patients with incomplete clinical data or follow-up information (II) Diagnosed with multiple primary malignancies
References
Publications (0)
Data not yet available
No reference posted for this study.